Join to View Full Profile
919 Conestoga RdBuilding One Suite 104Bryn Mawr, PA 19010
Phone+1 610-525-6400
Fax+1 610-525-4372
Dr. Wu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Crozer-Chester Medical CenterResidency, Obstetrics and Gynecology, 2004 - 2008
Lewis Katz School of Medicine at Temple UniversityClass of 2004
Certifications & Licensure
PA State Medical License 2004 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSuite, Greenway Health, LLC, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Greenway Prime Suite, Greenway Health, LLC, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Greenway PrimeSUITE, Greenway Health, LLC, 2014, 2016-2017
Publications & Presentations
PubMed
- 6 citationsIndependent inheritance of genes regulating two subpopulations of mouse clonogenic keratinocyte stem cells.Natalia V. Popova, Naira E. Suleimanian, Ekaterina A. Stepanova, Kimberly A. Teti, Kai Q. Wu
The Journal of Investigative Dermatology. Symposium Proceedings. 2004-09-01 - 10 citationsIdentification of two keratinocyte stem cell regulatory loci implicated in skin carcinogenesis.Natalia V. Popova, Kimberly A. Teti, Kai Q. Wu, Rebecca J. Morris
Carcinogenesis. 2003-03-01 - 10 citationsEvidence that the keratinocyte colony number is genetically controlled.Natalia V. Popova, Kimberly A. Tryson, Kai Q. Wu, Rebecca J. Morris
Experimental Dermatology. 2002-12-01
Press Mentions
A Novel Cell Culture System Modeling the SARS-CoV-2 Life CycleMarch 12th, 2021
The Systemic Inflammation-Based Prognostic Score Predicts Postoperative Complications in Patients Undergoing PancreaticoduodenectomyMarch 9th, 2021
Key Milestone: The First Patient Successfully Dosed with the Candidate Drug SR419 for Peripheral Neuropathic PainSeptember 21st, 2020
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
